Venous Thromboembolism
Conditions
Keywords
Venous thromboembolism, anticoagulant, treatment pattern, bleed
Brief summary
This study is a retrospective, observational, nationwide population-based cohort study utilizing the South Korea's Health Insurance and Review Assessment Service (HIRA) database. The aims of this study are to describe the sociodemographic and clinical characteristics of patients with venous thromboembolism according to their anticoagulant treatment (parenteral anticoagulants, warfarin, or non-vitamin K antagonist oral anticoagulants), to describe the treatment patterns related to anticoagulants, and to examine the risk of major bleeding according to the specific type of oral anticoagulants. The study will be conducted in two phases: Phase I for descriptive study and Phase II for comparative study.
Interventions
DRUGParenteral anticoagulant
Parenteral anticoagulant only
DRUGWarfarin
Warfarin-based
DRUGApixaban
Apixaban
DRUGRivaroxaban
Rivaroxaban
DRUGDabigatran
Dabigatran
DRUGEdoxaban
Edoxaban
Sponsors
Pfizer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Incident VTE diagnosis in an inpatient or outpatient setting between 1 Mar 2013 and 30 Jun 2019 2. Received anticoagulation therapy (all medication codes for anticoagulants approved for VTE in Korea; UFH, LMWH, warfarin, and NOACs) within 30 days of their VTE diagnosis (the index date will be defined as the date of treatment initiation with anticoagulants) 3. Aged ≥18 years at index date
Exclusion criteria
1. Had a record of VTE diagnosis within the 12-month period prior to the index VTE encounter. 2. Diagnosed with atrial fibrillation/flutter, mechanical heart valve replacement or mitral stenosis anytime prior to index date 3. Had a record of Inferior Vena Cava filter anytime prior to index date 4. Received anticoagulatory therapy within the 12-month period prior to index VTE encounter 5. Prescribed two different anticoagulants on the same index date 6. Had a record of pregnancy within the 9-month period prior to index date 7. Had a record of active cancer within the past 6 months of period prior to index date
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Interruption in Index Anticoagulant Treatment | From index date up to treatment interruption, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Treatment interruption was defined as when a participant had a gap with no new treatment within 30 days of the estimated end of supply of index treatment, but subsequently restarted the index treatment after this period of 30 days. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event. |
| Time to Treatment Interruption | From index date up to treatment interruption, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Treatment interruption was defined as when a participant had a gap with no new treatment within 30 days of the estimated end of supply of index treatment, but subsequently restarted the index treatment after this period of 30 days. The time to treatment interruption was defined as the period from the index date to the date of treatment interruption. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event. |
| Number of Participants Who Switched to Another Anticoagulant Therapy | From index date up to treatment switch, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Treatment switching was defined as a prescription of another anticoagulant therapy that was started after the treatment initiation of the index anticoagulant treatment and within 30 days after the estimated end of supply of the index anticoagulant drug (exposure to the new anticoagulant treatment must last for at least 30 days to be considered as a treatment switch). The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event. |
| Time to Treatment Switch | From index date up to treatment switch, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Treatment switching was defined as a prescription of another anticoagulant therapy that was started after the treatment initiation of the index anticoagulant treatment and within 30 days after the estimated end of supply of the index anticoagulant drug (exposure to the new anticoagulant treatment must last for at least 30 days to be considered as a treatment switch). The time to treatment switch was defined as the period from the index date to the date of treatment switch. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event. |
| Number of Participants Who Completely Discontinued Index Anticoagulant Treatment | From index date up to treatment discontinuation, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Treatment discontinuation (complete discontinuation; no reinitiation) was defined as when a participant who ended their first continuous treatment episode with the index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event. |
| Time to Treatment Discontinuation | From index date up to treatment discontinuation, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Treatment discontinuation (complete discontinuation; no reinitiation) was defined as when a participant who ended their first continuous treatment episode with the index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time. The time to treatment discontinuation was defined as the period from the index date to the date of treatment discontinuation. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event. |
| Overall Index Anticoagulant Treatment Duration | From index date up to the earliest of treatment interruption, switch, or discontinuation; during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Overall anticoagulant treatment duration was defined as the time period from the index date to the earliest of treatment interruption, switch, or discontinuation. Treatment interruption: when a participant had a gap with no new treatment within 30 days of estimated end of supply of index treatment, but subsequently restarted index treatment after this period of 30 days. Treatment switching: a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Treatment discontinuation: when a participant who ended their first continuous treatment episode with index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event. |
| Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months | Within 3 months of index date, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Participants were considered to be persistent on index anticoagulant treatment if a participant had evidence of a repeat prescription within 30 days of the end of their prescription and does not experience any of the events that included treatment interruption (participant had a gap with no new treatment within 30 days of estimated end of supply of index treatment, but subsequently restarted index treatment after 30 days), switch (prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug), or discontinuation (participant ended their first continuous treatment episode with index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time). Index date: date of first prescription for anticoagulants within 30 days after the index VTE event. |
| Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months | Within 6 months of index date, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Participants were considered to be persistent on index anticoagulant treatment if a participant had evidence of a repeat prescription within 30 days of the end of their prescription and does not experience any of the events that included treatment interruption (participant had a gap with no new treatment within 30 days of estimated end of supply of index treatment, but subsequently restarted index treatment after 30 days), switch (prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug), or discontinuation (participant ended their first continuous treatment episode with index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time). Index date: date of first prescription for anticoagulants within 30 days after the index VTE event. |
| Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Within 30 days before treatment interruption during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment interruption. Treatment interruption was defined as when a participant had a gap with no new treatment within 30 days of the estimated end of supply of index treatment, but subsequently restarted the index treatment after this period of 30 days. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. |
| Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event major bleeding are reported. |
| Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event complications of VTE are reported. |
| Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event thromboembolism are reported. |
| Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event major surgery are reported. |
| Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event cancer-related event are reported among participants without active cancer. Data not collected and reported for participants with active because all participants already had cancer. |
| Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event kidney function change are reported. |
| Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event liver function change are reported. |
| Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Within 30 days before treatment discontinuation during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study) | Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment discontinuation. Treatment discontinuation (complete discontinuation; no reinitiation) was defined as when a participant who ended their first continuous treatment episode with the index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. |
Countries
South Korea
Participant flow
Recruitment details
Data of participants diagnosed with venous thromboembolism (VTE) between 1 Mar 2013 and 30 Jun 2019 and received first prescription of anticoagulants within 30 days of VTE diagnosis in real world clinical practice, were retrieved from South Korea's health insurance review and assessment service (HIRA) database. Available data were extracted and evaluated during approximately 1 month of this retrospective observational study.
Pre-assignment details
Study was to be conducted in 2 phases. Phase 1: to describe anticoagulant treatment pattern according to index VTE treatment (PAC only, warfarin based, NOAC based treatment). Phase 2: to compare risk of major bleeding according to specific type of OAC treatment. But, as assessed by real world data review committee Phase 2 was not conducted due to insufficient statistical power that would lead to small and imbalanced sample sizes in comparison groups. Only Phase 1 data were studied and reported.
Participants by arm
| Arm | Count |
|---|---|
| Warfarin-Based Therapy Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort. | 11,208 |
| NOAC-Based Therapy: Apixaban Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort. | 5,047 |
| NOAC-Based Therapy: Dabigatran Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort. | 2,103 |
| NOAC-Based Therapy: Edoxaban Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort. | 2,342 |
| NOAC-Based Therapy: Rivaroxaban Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort. | 26,276 |
| PAC Only Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort. | 8,783 |
| Total | 55,759 |
Baseline characteristics
| Characteristic | Total | PAC Only | NOAC-Based Therapy: Rivaroxaban | NOAC-Based Therapy: Edoxaban | NOAC-Based Therapy: Dabigatran | NOAC-Based Therapy: Apixaban | Warfarin-Based Therapy |
|---|---|---|---|---|---|---|---|
| Age, Customized With Active Cancer 18-40 years | 144 Participants | 59 Participants | 68 Participants | 4 Participants | 4 Participants | 2 Participants | 7 Participants |
| Age, Customized With Active Cancer 40-65 years | 2481 Participants | 927 Participants | 1007 Participants | 91 Participants | 54 Participants | 170 Participants | 232 Participants |
| Age, Customized With Active Cancer >=65 years | 4630 Participants | 1247 Participants | 2152 Participants | 169 Participants | 151 Participants | 332 Participants | 579 Participants |
| Age, Customized Without Active Cancer 18-40 years | 4092 Participants | 527 Participants | 2042 Participants | 142 Participants | 138 Participants | 269 Participants | 974 Participants |
| Age, Customized Without Active Cancer 40-65 years | 12977 Participants | 1643 Participants | 6456 Participants | 479 Participants | 481 Participants | 998 Participants | 2920 Participants |
| Age, Customized Without Active Cancer >=65 years | 31435 Participants | 4380 Participants | 14551 Participants | 1457 Participants | 1275 Participants | 3276 Participants | 6496 Participants |
| Charlson Comorbidity Index (CCI) With Active Cancer | 4.98 Units on a scale STANDARD_DEVIATION 2.96 | 5.09 Units on a scale STANDARD_DEVIATION 3 | 5.02 Units on a scale STANDARD_DEVIATION 2.99 | 4.69 Units on a scale STANDARD_DEVIATION 2.95 | 4.77 Units on a scale STANDARD_DEVIATION 2.77 | 4.74 Units on a scale STANDARD_DEVIATION 2.85 | 4.84 Units on a scale STANDARD_DEVIATION 2.83 |
| Charlson Comorbidity Index (CCI) Without Active Cancer | 1.22 Units on a scale STANDARD_DEVIATION 1.41 | 1.45 Units on a scale STANDARD_DEVIATION 1.61 | 1.15 Units on a scale STANDARD_DEVIATION 1.37 | 1.22 Units on a scale STANDARD_DEVIATION 1.38 | 1.21 Units on a scale STANDARD_DEVIATION 1.43 | 1.23 Units on a scale STANDARD_DEVIATION 1.37 | 1.21 Units on a scale STANDARD_DEVIATION 1.39 |
| HAS-BLED Score With Active Cancer | 2.35 Units on a scale STANDARD_DEVIATION 1.14 | 2.23 Units on a scale STANDARD_DEVIATION 1.17 | 2.38 Units on a scale STANDARD_DEVIATION 1.13 | 2.47 Units on a scale STANDARD_DEVIATION 1.14 | 2.46 Units on a scale STANDARD_DEVIATION 1.1 | 2.41 Units on a scale STANDARD_DEVIATION 1.07 | 2.45 Units on a scale STANDARD_DEVIATION 1.11 |
| HAS-BLED Score Without Active Cancer | 2.20 Units on a scale STANDARD_DEVIATION 1.13 | 2.26 Units on a scale STANDARD_DEVIATION 1.18 | 2.16 Units on a scale STANDARD_DEVIATION 1.11 | 2.24 Units on a scale STANDARD_DEVIATION 1.1 | 2.24 Units on a scale STANDARD_DEVIATION 1.1 | 2.31 Units on a scale STANDARD_DEVIATION 1.09 | 2.19 Units on a scale STANDARD_DEVIATION 1.16 |
| Number of Participants According to Health Insurance Type With Active Cancer Medical aid | 460 Participants | 109 Participants | 213 Participants | 23 Participants | 14 Participants | 33 Participants | 68 Participants |
| Number of Participants According to Health Insurance Type With Active Cancer National Health Insurance | 6791 Participants | 2123 Participants | 3014 Participants | 240 Participants | 195 Participants | 471 Participants | 748 Participants |
| Number of Participants According to Health Insurance Type With Active Cancer Veterans | 4 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 2 Participants |
| Number of Participants According to Health Insurance Type Without Active Cancer Medical aid | 4386 Participants | 698 Participants | 1953 Participants | 188 Participants | 191 Participants | 387 Participants | 969 Participants |
| Number of Participants According to Health Insurance Type Without Active Cancer National Health Insurance | 44099 Participants | 5845 Participants | 21088 Participants | 1889 Participants | 1703 Participants | 4156 Participants | 9418 Participants |
| Number of Participants According to Health Insurance Type Without Active Cancer Veterans | 19 Participants | 7 Participants | 8 Participants | 1 Participants | 0 Participants | 0 Participants | 3 Participants |
| Number of Participants According to Type of Index VTE Event With Active Cancer DVT only | 2196 Participants | 735 Participants | 918 Participants | 71 Participants | 44 Participants | 164 Participants | 264 Participants |
| Number of Participants According to Type of Index VTE Event With Active Cancer PE with/without DVT | 5059 Participants | 1498 Participants | 2309 Participants | 193 Participants | 165 Participants | 340 Participants | 554 Participants |
| Number of Participants According to Type of Index VTE Event Without Active Cancer DVT only | 21426 Participants | 2822 Participants | 10919 Participants | 689 Participants | 499 Participants | 2265 Participants | 4232 Participants |
| Number of Participants According to Type of Index VTE Event Without Active Cancer PE with/without DVT | 27078 Participants | 3728 Participants | 12130 Participants | 1389 Participants | 1395 Participants | 2278 Participants | 6158 Participants |
| Number of Participants Classified According to the Index Year With Active Cancer 2012 | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Number of Participants Classified According to the Index Year With Active Cancer 2013 | 662 Participants | 244 Participants | 165 Participants | 0 Participants | 0 Participants | 0 Participants | 253 Participants |
| Number of Participants Classified According to the Index Year With Active Cancer 2014 | 1020 Participants | 366 Participants | 441 Participants | 0 Participants | 0 Participants | 0 Participants | 213 Participants |
| Number of Participants Classified According to the Index Year With Active Cancer 2015 | 1066 Participants | 381 Participants | 503 Participants | 0 Participants | 32 Participants | 19 Participants | 131 Participants |
| Number of Participants Classified According to the Index Year With Active Cancer 2016 | 1188 Participants | 361 Participants | 605 Participants | 14 Participants | 65 Participants | 64 Participants | 79 Participants |
| Number of Participants Classified According to the Index Year With Active Cancer 2017 | 1244 Participants | 355 Participants | 584 Participants | 43 Participants | 66 Participants | 117 Participants | 79 Participants |
| Number of Participants Classified According to the Index Year With Active Cancer 2018 | 1350 Participants | 358 Participants | 631 Participants | 109 Participants | 31 Participants | 174 Participants | 47 Participants |
| Number of Participants Classified According to the Index Year With Active Cancer 2019 | 725 Participants | 168 Participants | 298 Participants | 98 Participants | 15 Participants | 130 Participants | 16 Participants |
| Number of Participants Classified According to the Index Year Without Active Cancer 2012 | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Number of Participants Classified According to the Index Year Without Active Cancer 2013 | 4928 Participants | 804 Participants | 1085 Participants | 0 Participants | 4 Participants | 0 Participants | 3035 Participants |
| Number of Participants Classified According to the Index Year Without Active Cancer 2014 | 6585 Participants | 955 Participants | 2994 Participants | 0 Participants | 3 Participants | 2 Participants | 2631 Participants |
| Number of Participants Classified According to the Index Year Without Active Cancer 2015 | 7284 Participants | 1012 Participants | 4039 Participants | 0 Participants | 345 Participants | 224 Participants | 1664 Participants |
| Number of Participants Classified According to the Index Year Without Active Cancer 2016 | 8025 Participants | 1118 Participants | 4160 Participants | 182 Participants | 540 Participants | 837 Participants | 1188 Participants |
| Number of Participants Classified According to the Index Year Without Active Cancer 2017 | 8498 Participants | 1116 Participants | 4215 Participants | 537 Participants | 547 Participants | 1144 Participants | 939 Participants |
| Number of Participants Classified According to the Index Year Without Active Cancer 2018 | 8763 Participants | 1021 Participants | 4438 Participants | 825 Participants | 304 Participants | 1496 Participants | 679 Participants |
| Number of Participants Classified According to the Index Year Without Active Cancer 2019 | 4421 Participants | 524 Participants | 2118 Participants | 534 Participants | 151 Participants | 840 Participants | 254 Participants |
| Number of Participants With Comorbidities Antiphospholipid syndrome: With Active Cancer | 199 Participants | 87 Participants | 91 Participants | 4 Participants | 1 Participants | 8 Participants | 8 Participants |
| Number of Participants With Comorbidities Antiphospholipid syndrome: Without Active Cancer | 1113 Participants | 76 Participants | 589 Participants | 41 Participants | 42 Participants | 85 Participants | 280 Participants |
| Number of Participants With Comorbidities Asthma: With Active Cancer | 608 Participants | 152 Participants | 271 Participants | 23 Participants | 26 Participants | 44 Participants | 92 Participants |
| Number of Participants With Comorbidities Asthma: Without Active Cancer | 4944 Participants | 546 Participants | 2351 Participants | 236 Participants | 203 Participants | 424 Participants | 1184 Participants |
| Number of Participants With Comorbidities Chronic kidney disease: With Active Cancer | 157 Participants | 40 Participants | 60 Participants | 6 Participants | 5 Participants | 14 Participants | 32 Participants |
| Number of Participants With Comorbidities Chronic kidney disease: Without Active Cancer | 985 Participants | 215 Participants | 294 Participants | 45 Participants | 32 Participants | 87 Participants | 312 Participants |
| Number of Participants With Comorbidities Chronic liver disease: With Active Cancer | 1019 Participants | 339 Participants | 456 Participants | 37 Participants | 28 Participants | 68 Participants | 91 Participants |
| Number of Participants With Comorbidities Chronic liver disease: Without Active Cancer | 3743 Participants | 537 Participants | 1723 Participants | 145 Participants | 146 Participants | 392 Participants | 800 Participants |
| Number of Participants With Comorbidities COPD: With Active Cancer | 1452 Participants | 390 Participants | 706 Participants | 50 Participants | 46 Participants | 81 Participants | 179 Participants |
| Number of Participants With Comorbidities COPD: Without Active Cancer | 7950 Participants | 1010 Participants | 3765 Participants | 370 Participants | 332 Participants | 707 Participants | 1766 Participants |
| Number of Participants With Comorbidities Diabetes mellitus: With Active Cancer | 1519 Participants | 455 Participants | 695 Participants | 65 Participants | 51 Participants | 92 Participants | 161 Participants |
| Number of Participants With Comorbidities Diabetes mellitus: Without Active Cancer | 8625 Participants | 1454 Participants | 3826 Participants | 335 Participants | 326 Participants | 866 Participants | 1818 Participants |
| Number of Participants With Comorbidities Fracture: With Active Cancer | 430 Participants | 118 Participants | 202 Participants | 15 Participants | 15 Participants | 37 Participants | 43 Participants |
| Number of Participants With Comorbidities Fracture: Without Active Cancer | 5582 Participants | 802 Participants | 2601 Participants | 273 Participants | 258 Participants | 511 Participants | 1137 Participants |
| Number of Participants With Comorbidities Heart failure: With Active Cancer | 146 Participants | 35 Participants | 67 Participants | 1 Participants | 6 Participants | 8 Participants | 29 Participants |
| Number of Participants With Comorbidities Heart failure: Without Active Cancer | 2146 Participants | 273 Participants | 906 Participants | 123 Participants | 99 Participants | 207 Participants | 538 Participants |
| Number of Participants With Comorbidities History of cancer: With Active Cancer | 0 Participants | — | — | — | — | — | — |
| Number of Participants With Comorbidities History of cancer: Without Active Cancer | 5206 Participants | 904 Participants | 2432 Participants | 253 Participants | 196 Participants | 524 Participants | 897 Participants |
| Number of Participants With Comorbidities Hyperlipidemia: With Active Cancer | 1302 Participants | 377 Participants | 584 Participants | 68 Participants | 44 Participants | 99 Participants | 130 Participants |
| Number of Participants With Comorbidities Hyperlipidemia: Without Active Cancer | 9300 Participants | 1225 Participants | 4452 Participants | 432 Participants | 363 Participants | 1093 Participants | 1735 Participants |
| Number of Participants With Comorbidities Hypertension: With Active Cancer | 2772 Participants | 772 Participants | 1284 Participants | 97 Participants | 79 Participants | 205 Participants | 335 Participants |
| Number of Participants With Comorbidities Hypertension: Without Active Cancer | 20947 Participants | 2916 Participants | 9679 Participants | 920 Participants | 821 Participants | 2086 Participants | 4525 Participants |
| Number of Participants With Comorbidities Ischemic heart disease: With Active Cancer | 121 Participants | 25 Participants | 60 Participants | 8 Participants | 3 Participants | 10 Participants | 15 Participants |
| Number of Participants With Comorbidities Ischemic heart disease: Without Active Cancer | 1084 Participants | 201 Participants | 463 Participants | 60 Participants | 34 Participants | 91 Participants | 235 Participants |
| Number of Participants With Comorbidities Myocardial infarction: With Active Cancer | 24 Participants | 8 Participants | 8 Participants | 0 Participants | 0 Participants | 4 Participants | 4 Participants |
| Number of Participants With Comorbidities Myocardial infarction: Without Active Cancer | 271 Participants | 89 Participants | 88 Participants | 6 Participants | 10 Participants | 25 Participants | 53 Participants |
| Number of Participants With Comorbidities Stroke: With Active Cancer | 383 Participants | 96 Participants | 172 Participants | 15 Participants | 17 Participants | 27 Participants | 56 Participants |
| Number of Participants With Comorbidities Stroke: Without Active Cancer | 4535 Participants | 796 Participants | 1987 Participants | 220 Participants | 182 Participants | 394 Participants | 956 Participants |
| Number of Participants With Comorbidities Trauma: With Active Cancer | 14 Participants | 4 Participants | 8 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Number of Participants With Comorbidities Trauma: Without Active Cancer | 148 Participants | 20 Participants | 67 Participants | 4 Participants | 4 Participants | 10 Participants | 43 Participants |
| Number of Participants With Major Orthopedic Surgery-provoked VTE With Active Cancer | 22 Participants | 6 Participants | 10 Participants | 1 Participants | 1 Participants | 2 Participants | 2 Participants |
| Number of Participants With Major Orthopedic Surgery-provoked VTE Without Active Cancer | 956 Participants | 119 Participants | 480 Participants | 43 Participants | 53 Participants | 78 Participants | 183 Participants |
| Number of Participants With Previous use of Medications ACE inhibitors: With Active Cancer | 4173 Participants | 1163 Participants | 1920 Participants | 160 Participants | 122 Participants | 295 Participants | 513 Participants |
| Number of Participants With Previous use of Medications ACE inhibitors: Without Active Cancer | 21886 Participants | 3052 Participants | 10036 Participants | 1005 Participants | 867 Participants | 2086 Participants | 4840 Participants |
| Number of Participants With Previous use of Medications Angiotensin II receptor blockers: With Active Cancer | 3243 Participants | 888 Participants | 1492 Participants | 130 Participants | 103 Participants | 233 Participants | 397 Participants |
| Number of Participants With Previous use of Medications Angiotensin II receptor blockers: Without Active Cancer | 23724 Participants | 3283 Participants | 10925 Participants | 1108 Participants | 961 Participants | 2364 Participants | 5083 Participants |
| Number of Participants With Previous use of Medications Antiplatelets: With Active Cancer | 1932 Participants | 507 Participants | 895 Participants | 84 Participants | 58 Participants | 159 Participants | 229 Participants |
| Number of Participants With Previous use of Medications Antiplatelets: Without Active Cancer | 18694 Participants | 2773 Participants | 8580 Participants | 868 Participants | 752 Participants | 1763 Participants | 3958 Participants |
| Number of Participants With Previous use of Medications Beta-blockers: With Active Cancer | 1164 Participants | 293 Participants | 547 Participants | 53 Participants | 44 Participants | 72 Participants | 155 Participants |
| Number of Participants With Previous use of Medications Beta-blockers: Without Active Cancer | 9232 Participants | 1272 Participants | 4218 Participants | 432 Participants | 361 Participants | 825 Participants | 2124 Participants |
| Number of Participants With Previous use of Medications Calcium-channel blockers: With Active Cancer | 2535 Participants | 698 Participants | 1161 Participants | 102 Participants | 82 Participants | 181 Participants | 311 Participants |
| Number of Participants With Previous use of Medications Calcium-channel blockers: Without Active Cancer | 16777 Participants | 2436 Participants | 7703 Participants | 778 Participants | 658 Participants | 1680 Participants | 3522 Participants |
| Number of Participants With Previous use of Medications Corticosteroids: With Active Cancer | 4516 Participants | 1403 Participants | 2066 Participants | 129 Participants | 121 Participants | 266 Participants | 531 Participants |
| Number of Participants With Previous use of Medications Corticosteroids: Without Active Cancer | 21326 Participants | 2492 Participants | 10415 Participants | 726 Participants | 797 Participants | 1787 Participants | 5109 Participants |
| Number of Participants With Previous use of Medications Cyclooxygenase-2 inhibitors: With Active Cancer | 745 Participants | 216 Participants | 332 Participants | 26 Participants | 29 Participants | 70 Participants | 72 Participants |
| Number of Participants With Previous use of Medications Cyclooxygenase-2 inhibitors: Without Active Cancer | 7862 Participants | 929 Participants | 3956 Participants | 389 Participants | 360 Participants | 1044 Participants | 1184 Participants |
| Number of Participants With Previous use of Medications Diuretics: With Active Cancer | 2860 Participants | 770 Participants | 1379 Participants | 113 Participants | 78 Participants | 183 Participants | 337 Participants |
| Number of Participants With Previous use of Medications Diuretics: Without Active Cancer | 9242 Participants | 1306 Participants | 4066 Participants | 425 Participants | 379 Participants | 796 Participants | 2270 Participants |
| Number of Participants With Previous use of Medications Estrogens: With Active Cancer | 142 Participants | 37 Participants | 62 Participants | 3 Participants | 5 Participants | 12 Participants | 23 Participants |
| Number of Participants With Previous use of Medications Estrogens: Without Active Cancer | 916 Participants | 108 Participants | 466 Participants | 43 Participants | 21 Participants | 96 Participants | 182 Participants |
| Number of Participants With Previous use of Medications NSAIDs: With Active Cancer | 5769 Participants | 1704 Participants | 2601 Participants | 225 Participants | 172 Participants | 397 Participants | 670 Participants |
| Number of Participants With Previous use of Medications NSAIDs: Without Active Cancer | 38375 Participants | 4774 Participants | 18695 Participants | 1622 Participants | 1492 Participants | 3657 Participants | 8135 Participants |
| Number of Participants With Previous use of Medications Proton pump inhibitors: With Active Cancer | 3637 Participants | 1057 Participants | 1656 Participants | 152 Participants | 112 Participants | 262 Participants | 398 Participants |
| Number of Participants With Previous use of Medications Proton pump inhibitors: Without Active Cancer | 15529 Participants | 1925 Participants | 7550 Participants | 759 Participants | 693 Participants | 1607 Participants | 2995 Participants |
| Number of Participants With Previous use of Medications SSRI: With Active Cancer | 391 Participants | 98 Participants | 190 Participants | 17 Participants | 17 Participants | 28 Participants | 41 Participants |
| Number of Participants With Previous use of Medications SSRI: Without Active Cancer | 3892 Participants | 464 Participants | 1913 Participants | 216 Participants | 170 Participants | 404 Participants | 725 Participants |
| Number of Participants With Previous use of Medications Thiazides: With Active Cancer | 902 Participants | 245 Participants | 403 Participants | 28 Participants | 22 Participants | 65 Participants | 139 Participants |
| Number of Participants With Previous use of Medications Thiazides: Without Active Cancer | 9140 Participants | 1133 Participants | 4253 Participants | 385 Participants | 359 Participants | 842 Participants | 2168 Participants |
| Number of Participants With Previous use of Medications Triazole antifungal agents: With Active Cancer | 460 Participants | 120 Participants | 219 Participants | 20 Participants | 13 Participants | 33 Participants | 55 Participants |
| Number of Participants With Previous use of Medications Triazole antifungal agents: Without Active Cancer | 3420 Participants | 383 Participants | 1675 Participants | 129 Participants | 130 Participants | 329 Participants | 774 Participants |
| Number of Participants With Previous use of Medications Vasodilators: With Active Cancer | 1042 Participants | 274 Participants | 467 Participants | 45 Participants | 42 Participants | 86 Participants | 128 Participants |
| Number of Participants With Previous use of Medications Vasodilators: Without Active Cancer | 11800 Participants | 1593 Participants | 5595 Participants | 505 Participants | 466 Participants | 1109 Participants | 2532 Participants |
| Race and Ethnicity Not Collected | 0 Participants | — | — | — | — | — | — |
| Sex: Female, Male With Active Cancer Female | 3489 Participants | 1095 Participants | 1526 Participants | 117 Participants | 101 Participants | 256 Participants | 394 Participants |
| Sex: Female, Male With Active Cancer Male | 3766 Participants | 1138 Participants | 1701 Participants | 147 Participants | 108 Participants | 248 Participants | 424 Participants |
| Sex: Female, Male Without Active Cancer Female | 28519 Participants | 3671 Participants | 13498 Participants | 1288 Participants | 1126 Participants | 2958 Participants | 5978 Participants |
| Sex: Female, Male Without Active Cancer Male | 19985 Participants | 2879 Participants | 9551 Participants | 790 Participants | 768 Participants | 1585 Participants | 4412 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 |
Outcome results
Primary
Number of Participants Who Completely Discontinued Index Anticoagulant Treatment
Treatment discontinuation (complete discontinuation; no reinitiation) was defined as when a participant who ended their first continuous treatment episode with the index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event.
Time frame: From index date up to treatment discontinuation, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)
Population: Analysis population included all eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as one entity, while individual NOAC results discriminated between each NOAC, therefore total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Here, Number Analyzed signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Warfarin-Based Therapy | Number of Participants Who Completely Discontinued Index Anticoagulant Treatment | Without Active Cancer | 4707 Participants |
| Warfarin-Based Therapy | Number of Participants Who Completely Discontinued Index Anticoagulant Treatment | With Active Cancer | 444 Participants |
| NOAC-Based Therapy | Number of Participants Who Completely Discontinued Index Anticoagulant Treatment | Without Active Cancer | 19826 Participants |
| NOAC-Based Therapy | Number of Participants Who Completely Discontinued Index Anticoagulant Treatment | With Active Cancer | 2570 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants Who Completely Discontinued Index Anticoagulant Treatment | Without Active Cancer | 2828 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants Who Completely Discontinued Index Anticoagulant Treatment | With Active Cancer | 279 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants Who Completely Discontinued Index Anticoagulant Treatment | Without Active Cancer | 1028 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants Who Completely Discontinued Index Anticoagulant Treatment | With Active Cancer | 115 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants Who Completely Discontinued Index Anticoagulant Treatment | Without Active Cancer | 1164 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants Who Completely Discontinued Index Anticoagulant Treatment | With Active Cancer | 147 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants Who Completely Discontinued Index Anticoagulant Treatment | Without Active Cancer | 14170 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants Who Completely Discontinued Index Anticoagulant Treatment | With Active Cancer | 1968 Participants |
| PAC Only | Number of Participants Who Completely Discontinued Index Anticoagulant Treatment | Without Active Cancer | 4534 Participants |
| PAC Only | Number of Participants Who Completely Discontinued Index Anticoagulant Treatment | With Active Cancer | 1449 Participants |
Primary
Number of Participants Who Switched to Another Anticoagulant Therapy
Treatment switching was defined as a prescription of another anticoagulant therapy that was started after the treatment initiation of the index anticoagulant treatment and within 30 days after the estimated end of supply of the index anticoagulant drug (exposure to the new anticoagulant treatment must last for at least 30 days to be considered as a treatment switch). The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event.
Time frame: From index date up to treatment switch, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)
Population: Analysis population included all eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as one entity, while individual NOAC results discriminated between each NOAC, therefore total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Here, Number Analyzed signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Warfarin-Based Therapy | Number of Participants Who Switched to Another Anticoagulant Therapy | Without Active Cancer | 1541 Participants |
| Warfarin-Based Therapy | Number of Participants Who Switched to Another Anticoagulant Therapy | With Active Cancer | 144 Participants |
| NOAC-Based Therapy | Number of Participants Who Switched to Another Anticoagulant Therapy | Without Active Cancer | 1273 Participants |
| NOAC-Based Therapy | Number of Participants Who Switched to Another Anticoagulant Therapy | With Active Cancer | 173 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants Who Switched to Another Anticoagulant Therapy | Without Active Cancer | 319 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants Who Switched to Another Anticoagulant Therapy | With Active Cancer | 33 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants Who Switched to Another Anticoagulant Therapy | Without Active Cancer | 276 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants Who Switched to Another Anticoagulant Therapy | With Active Cancer | 30 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants Who Switched to Another Anticoagulant Therapy | Without Active Cancer | 204 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants Who Switched to Another Anticoagulant Therapy | With Active Cancer | 26 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants Who Switched to Another Anticoagulant Therapy | Without Active Cancer | 1777 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants Who Switched to Another Anticoagulant Therapy | With Active Cancer | 208 Participants |
| PAC Only | Number of Participants Who Switched to Another Anticoagulant Therapy | Without Active Cancer | 535 Participants |
| PAC Only | Number of Participants Who Switched to Another Anticoagulant Therapy | With Active Cancer | 208 Participants |
Primary
Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months
Participants were considered to be persistent on index anticoagulant treatment if a participant had evidence of a repeat prescription within 30 days of the end of their prescription and does not experience any of the events that included treatment interruption (participant had a gap with no new treatment within 30 days of estimated end of supply of index treatment, but subsequently restarted index treatment after 30 days), switch (prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug), or discontinuation (participant ended their first continuous treatment episode with index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time). Index date: date of first prescription for anticoagulants within 30 days after the index VTE event.
Time frame: Within 3 months of index date, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)
Population: Analysis population included all eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as one entity, while individual NOAC results discriminated between each NOAC, therefore total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Here, Number Analyzed signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Warfarin-Based Therapy | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months | Without Active Cancer | 6313 Participants |
| Warfarin-Based Therapy | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months | With Active Cancer | 388 Participants |
| NOAC-Based Therapy | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months | Without Active Cancer | 19848 Participants |
| NOAC-Based Therapy | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months | With Active Cancer | 2405 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months | Without Active Cancer | 2390 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months | With Active Cancer | 290 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months | Without Active Cancer | 1225 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months | With Active Cancer | 120 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months | Without Active Cancer | 1395 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months | With Active Cancer | 148 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months | Without Active Cancer | 14037 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months | With Active Cancer | 1770 Participants |
| PAC Only | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months | Without Active Cancer | 222 Participants |
| PAC Only | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months | With Active Cancer | 673 Participants |
Primary
Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months
Participants were considered to be persistent on index anticoagulant treatment if a participant had evidence of a repeat prescription within 30 days of the end of their prescription and does not experience any of the events that included treatment interruption (participant had a gap with no new treatment within 30 days of estimated end of supply of index treatment, but subsequently restarted index treatment after 30 days), switch (prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug), or discontinuation (participant ended their first continuous treatment episode with index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time). Index date: date of first prescription for anticoagulants within 30 days after the index VTE event.
Time frame: Within 6 months of index date, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)
Population: Analysis population included all eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as one entity, while individual NOAC results discriminated between each NOAC, therefore total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Here, Number Analyzed signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Warfarin-Based Therapy | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months | Without Active Cancer | 4393 Participants |
| Warfarin-Based Therapy | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months | With Active Cancer | 217 Participants |
| NOAC-Based Therapy | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months | Without Active Cancer | 10557 Participants |
| NOAC-Based Therapy | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months | With Active Cancer | 1089 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months | Without Active Cancer | 1213 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months | With Active Cancer | 125 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months | Without Active Cancer | 606 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months | With Active Cancer | 46 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months | Without Active Cancer | 817 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months | With Active Cancer | 91 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months | Without Active Cancer | 7209 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months | With Active Cancer | 773 Participants |
| PAC Only | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months | Without Active Cancer | 75 Participants |
| PAC Only | Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months | With Active Cancer | 221 Participants |
Primary
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation
Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment discontinuation. Treatment discontinuation (complete discontinuation; no reinitiation) was defined as when a participant who ended their first continuous treatment episode with the index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event.
Time frame: Within 30 days before treatment discontinuation during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)
Population: All eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC,hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed:participants evaluable for this outcome measure with discontinuation event;Number Analyzed:participants evaluable for specified rows.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Kidney Function Changes: With Active Cancer | 14 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Thromboembolism: Without Active Cancer | 258 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Liver Function Change: With Active Cancer | 16 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Thromboembolism: With Active Cancer | 17 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Bleeding: Without Active Cancer | 42 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Surgery: Without Active Cancer | 78 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Surgery: With Active Cancer | 11 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Complications of VTE: Without Active Cancer | 10 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Liver Function Change: Without Active Cancer | 158 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Kidney Function Changes: Without Active Cancer | 104 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Complications of VTE: With Active Cancer | 1 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Cancer-related Event: Without Active Cancer | 133 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Bleeding: With Active Cancer | 7 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Surgery: With Active Cancer | 66 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Bleeding: With Active Cancer | 36 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Liver Function Change: Without Active Cancer | 452 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Complications of VTE: Without Active Cancer | 25 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Kidney Function Changes: With Active Cancer | 64 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Thromboembolism: Without Active Cancer | 777 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Bleeding: Without Active Cancer | 118 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Surgery: Without Active Cancer | 1691 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Thromboembolism: With Active Cancer | 122 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Cancer-related Event: Without Active Cancer | 307 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Liver Function Change: With Active Cancer | 50 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Complications of VTE: With Active Cancer | 2 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Kidney Function Changes: Without Active Cancer | 240 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Bleeding: Without Active Cancer | 13 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Thromboembolism: Without Active Cancer | 123 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Kidney Function Changes: With Active Cancer | 7 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Complications of VTE: Without Active Cancer | 4 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Cancer-related Event: Without Active Cancer | 40 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Liver Function Change: Without Active Cancer | 65 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Complications of VTE: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Bleeding: With Active Cancer | 4 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Surgery: With Active Cancer | 7 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Kidney Function Changes: Without Active Cancer | 39 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Surgery: Without Active Cancer | 508 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Liver Function Change: With Active Cancer | 3 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Thromboembolism: With Active Cancer | 14 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Liver Function Change: Without Active Cancer | 34 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Bleeding: Without Active Cancer | 7 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Complications of VTE: Without Active Cancer | 2 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Thromboembolism: Without Active Cancer | 48 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Surgery: Without Active Cancer | 18 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Cancer-related Event: Without Active Cancer | 14 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Kidney Function Changes: Without Active Cancer | 13 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Bleeding: With Active Cancer | 2 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Complications of VTE: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Thromboembolism: With Active Cancer | 9 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Surgery: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Kidney Function Changes: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Liver Function Change: With Active Cancer | 2 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Surgery: Without Active Cancer | 25 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Surgery: With Active Cancer | 5 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Thromboembolism: With Active Cancer | 11 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Bleeding: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Liver Function Change: With Active Cancer | 3 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Thromboembolism: Without Active Cancer | 53 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Cancer-related Event: Without Active Cancer | 20 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Bleeding: Without Active Cancer | 5 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Complications of VTE: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Kidney Function Changes: Without Active Cancer | 11 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Kidney Function Changes: With Active Cancer | 5 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Complications of VTE: Without Active Cancer | 3 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Liver Function Change: Without Active Cancer | 28 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Thromboembolism: Without Active Cancer | 537 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Bleeding: With Active Cancer | 29 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Cancer-related Event: Without Active Cancer | 232 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Complications of VTE: With Active Cancer | 2 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Surgery: Without Active Cancer | 1138 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Thromboembolism: With Active Cancer | 87 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Bleeding: Without Active Cancer | 90 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Surgery: With Active Cancer | 52 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Complications of VTE: Without Active Cancer | 15 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Liver Function Change: With Active Cancer | 42 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Kidney Function Changes: With Active Cancer | 51 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Liver Function Change: Without Active Cancer | 321 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Kidney Function Changes: Without Active Cancer | 172 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Bleeding: With Active Cancer | 14 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Surgery: Without Active Cancer | 625 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Liver Function Change: Without Active Cancer | 441 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Complications of VTE: With Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Kidney Function Changes: Without Active Cancer | 383 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Kidney Function Changes: With Active Cancer | 48 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Bleeding: Without Active Cancer | 20 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Thromboembolism: Without Active Cancer | 734 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Thromboembolism: With Active Cancer | 89 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Liver Function Change: With Active Cancer | 34 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Cancer-related Event: Without Active Cancer | 291 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Major Surgery: With Active Cancer | 190 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation | Complications of VTE: Without Active Cancer | 18 Participants |
Primary
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption
Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment interruption. Treatment interruption was defined as when a participant had a gap with no new treatment within 30 days of the estimated end of supply of index treatment, but subsequently restarted the index treatment after this period of 30 days. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event.
Time frame: Within 30 days before treatment interruption during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)
Population: All eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed: participants evaluable for this outcome measure with interruption event;Number Analyzed: participants evaluable for specified rows.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Kidney Function Changes: With Active Cancer | 1 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Thromboembolism: Without Active Cancer | 158 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Liver Function Change: With Active Cancer | 2 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Thromboembolism: With Active Cancer | 12 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Bleeding: Without Active Cancer | 27 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Surgery: Without Active Cancer | 92 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Surgery: With Active Cancer | 15 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Complications of VTE: Without Active Cancer | 6 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Liver Function Change: Without Active Cancer | 79 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Kidney Function Changes: Without Active Cancer | 45 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Complications of VTE: With Active Cancer | 1 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Cancer-related Event: Without Active Cancer | 62 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Bleeding: With Active Cancer | 1 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Surgery: With Active Cancer | 33 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Bleeding: With Active Cancer | 8 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Liver Function Change: Without Active Cancer | 158 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Complications of VTE: Without Active Cancer | 13 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Kidney Function Changes: With Active Cancer | 8 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Thromboembolism: Without Active Cancer | 328 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Bleeding: Without Active Cancer | 53 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Surgery: Without Active Cancer | 566 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Thromboembolism: With Active Cancer | 21 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Cancer-related Event: Without Active Cancer | 126 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Liver Function Change: With Active Cancer | 9 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Complications of VTE: With Active Cancer | 1 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Kidney Function Changes: Without Active Cancer | 87 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Bleeding: Without Active Cancer | 5 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Thromboembolism: Without Active Cancer | 50 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Kidney Function Changes: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Complications of VTE: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Cancer-related Event: Without Active Cancer | 14 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Liver Function Change: Without Active Cancer | 12 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Complications of VTE: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Bleeding: With Active Cancer | 3 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Surgery: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Kidney Function Changes: Without Active Cancer | 10 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Surgery: Without Active Cancer | 126 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Liver Function Change: With Active Cancer | 3 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Thromboembolism: With Active Cancer | 3 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Liver Function Change: Without Active Cancer | 7 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Bleeding: Without Active Cancer | 2 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Complications of VTE: Without Active Cancer | 3 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Thromboembolism: Without Active Cancer | 19 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Surgery: Without Active Cancer | 9 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Cancer-related Event: Without Active Cancer | 5 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Kidney Function Changes: Without Active Cancer | 8 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Bleeding: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Complications of VTE: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Thromboembolism: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Surgery: With Active Cancer | 2 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Kidney Function Changes: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Liver Function Change: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Surgery: Without Active Cancer | 17 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Surgery: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Thromboembolism: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Bleeding: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Liver Function Change: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Thromboembolism: Without Active Cancer | 18 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Cancer-related Event: Without Active Cancer | 4 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Bleeding: Without Active Cancer | 2 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Complications of VTE: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Kidney Function Changes: Without Active Cancer | 7 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Kidney Function Changes: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Complications of VTE: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Liver Function Change: Without Active Cancer | 6 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Thromboembolism: Without Active Cancer | 233 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Bleeding: With Active Cancer | 4 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Cancer-related Event: Without Active Cancer | 99 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Complications of VTE: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Surgery: Without Active Cancer | 407 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Thromboembolism: With Active Cancer | 17 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Bleeding: Without Active Cancer | 42 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Surgery: With Active Cancer | 27 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Complications of VTE: Without Active Cancer | 10 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Liver Function Change: With Active Cancer | 5 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Kidney Function Changes: With Active Cancer | 7 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Liver Function Change: Without Active Cancer | 129 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Kidney Function Changes: Without Active Cancer | 55 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Bleeding: With Active Cancer | 2 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Surgery: Without Active Cancer | 171 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Liver Function Change: Without Active Cancer | 72 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Complications of VTE: With Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Kidney Function Changes: Without Active Cancer | 44 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Kidney Function Changes: With Active Cancer | 10 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Bleeding: Without Active Cancer | 4 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Thromboembolism: Without Active Cancer | 209 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Thromboembolism: With Active Cancer | 9 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Liver Function Change: With Active Cancer | 9 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Cancer-related Event: Without Active Cancer | 100 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Major Surgery: With Active Cancer | 55 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption | Complications of VTE: Without Active Cancer | 5 Participants |
Primary
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event
Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event cancer-related event are reported among participants without active cancer. Data not collected and reported for participants with active because all participants already had cancer.
Time frame: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)
Population: All eligible participants. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed: participants evaluable for this outcome measure with switch event. Number Analyzed (n): participants evaluable for specified rows. n =0 as switch in the same treatment arm not feasible.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Dabigatran: Without Active Cancer | 1 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Apixaban: Without Active Cancer | 5 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to NOAC: Without Active Cancer | 26 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to PAC: Without Active Cancer | 24 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Rivaroxaban: Without Active Cancer | 19 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Edoxaban: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Warfarin: Without Active Cancer | 13 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to PAC: Without Active Cancer | 32 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to PAC: Without Active Cancer | 2 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Rivaroxaban: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Dabigatran: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Warfarin: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Edoxaban: Without Active Cancer | 2 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to PAC: Without Active Cancer | 2 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Edoxaban: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Rivaroxaban: Without Active Cancer | 3 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Warfarin: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Apixaban: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Apixaban: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to PAC: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Rivaroxaban: Without Active Cancer | 5 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Dabigatran: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Warfarin: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Apixaban: Without Active Cancer | 6 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Warfarin: Without Active Cancer | 11 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to PAC: Without Active Cancer | 27 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Dabigatran: Without Active Cancer | 3 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Edoxaban: Without Active Cancer | 3 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Edoxaban: Without Active Cancer | 6 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Dabigatran: Without Active Cancer | 5 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Apixaban: Without Active Cancer | 11 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to NOAC: Without Active Cancer | 57 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Warfarin: Without Active Cancer | 6 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event | Switched to Rivaroxaban: Without Active Cancer | 35 Participants |
Primary
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE
Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event complications of VTE are reported.
Time frame: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)
Population: All eligible participants. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed: participants evaluable for this outcome measure with switch event. Number Analyzed (n): participants evaluable for specified rows. n =0 as switch in the same treatment arm not feasible.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Dabigatran: Without Active Cancer | 1 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Apixaban: Without Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Edoxaban: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Dabigatran: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Apixaban: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to PAC: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to NOAC: Without Active Cancer | 2 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to NOAC: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to PAC: Without Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Rivaroxaban: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Rivaroxaban: Without Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Edoxaban: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Warfarin: Without Active Cancer | 12 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to PAC: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Warfarin: With Active Cancer | 0 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to PAC: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Dabigatran: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Warfarin: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Rivaroxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to PAC: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Rivaroxaban: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Dabigatran: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Warfarin: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to PAC: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Edoxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Edoxaban: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to PAC: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Apixaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Apixaban: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Rivaroxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to PAC: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Edoxaban: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Rivaroxaban: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Warfarin: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Edoxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Warfarin: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Apixaban: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Warfarin: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Warfarin: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Dabigatran: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Apixaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to PAC: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Dabigatran: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Rivaroxaban: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Rivaroxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to PAC: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Warfarin: Without Active Cancer | 11 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Apixaban: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Dabigatran: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Edoxaban: Without Active Cancer | 2 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Warfarin: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to PAC: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Apixaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Dabigatran: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Edoxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to PAC: Without Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Dabigatran: Without Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Dabigatran: With Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to NOAC: With Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to NOAC: Without Active Cancer | 2 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Warfarin: With Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Apixaban: Without Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Edoxaban: With Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Rivaroxaban: Without Active Cancer | 2 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Edoxaban: Without Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Apixaban: With Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Rivaroxaban: With Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE | Switched to Warfarin: Without Active Cancer | 1 Participants |
Primary
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change
Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event kidney function change are reported.
Time frame: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)
Population: All eligible participants. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed: participants evaluable for this outcome measure with switch event. Number Analyzed (n): participants evaluable for specified rows. n =0 as switch in the same treatment arm not feasible.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Dabigatran: Without Active Cancer | 1 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Apixaban: Without Active Cancer | 3 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Edoxaban: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Dabigatran: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Apixaban: With Active Cancer | 1 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to PAC: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to NOAC: Without Active Cancer | 22 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to NOAC: With Active Cancer | 2 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to PAC: Without Active Cancer | 6 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Rivaroxaban: With Active Cancer | 1 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Rivaroxaban: Without Active Cancer | 17 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Edoxaban: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Warfarin: Without Active Cancer | 13 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to PAC: Without Active Cancer | 5 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Warfarin: With Active Cancer | 2 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to PAC: With Active Cancer | 4 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Dabigatran: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Warfarin: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Rivaroxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to PAC: Without Active Cancer | 3 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Rivaroxaban: Without Active Cancer | 2 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Dabigatran: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Warfarin: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to PAC: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Edoxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Edoxaban: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to PAC: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Apixaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Apixaban: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Rivaroxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to PAC: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Edoxaban: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Rivaroxaban: Without Active Cancer | 2 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Warfarin: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Edoxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Warfarin: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Apixaban: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Warfarin: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Warfarin: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Dabigatran: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Apixaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to PAC: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Dabigatran: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Rivaroxaban: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Rivaroxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to PAC: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Warfarin: Without Active Cancer | 12 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Apixaban: Without Active Cancer | 10 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Dabigatran: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Edoxaban: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Warfarin: With Active Cancer | 2 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to PAC: With Active Cancer | 3 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Apixaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Dabigatran: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Edoxaban: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to PAC: Without Active Cancer | 2 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Dabigatran: Without Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Dabigatran: With Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to NOAC: With Active Cancer | 2 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to NOAC: Without Active Cancer | 4 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Warfarin: With Active Cancer | 1 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Apixaban: Without Active Cancer | 1 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Edoxaban: With Active Cancer | 1 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Rivaroxaban: Without Active Cancer | 2 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Edoxaban: Without Active Cancer | 1 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Apixaban: With Active Cancer | 1 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Rivaroxaban: With Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change | Switched to Warfarin: Without Active Cancer | 5 Participants |
Primary
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change
Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event liver function change are reported.
Time frame: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)
Population: All eligible participants. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed: participants evaluable for this outcome measure with switch event. Number Analyzed (n): participants evaluable for specified rows. n =0 as switch in the same treatment arm not feasible.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Dabigatran: Without Active Cancer | 6 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Apixaban: Without Active Cancer | 3 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Edoxaban: With Active Cancer | 1 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Dabigatran: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Apixaban: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to PAC: With Active Cancer | 3 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to NOAC: Without Active Cancer | 63 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to NOAC: With Active Cancer | 1 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to PAC: Without Active Cancer | 7 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Rivaroxaban: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Rivaroxaban: Without Active Cancer | 51 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Edoxaban: Without Active Cancer | 3 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Warfarin: Without Active Cancer | 36 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to PAC: Without Active Cancer | 11 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Warfarin: With Active Cancer | 3 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to PAC: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Dabigatran: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Warfarin: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Rivaroxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to PAC: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Rivaroxaban: Without Active Cancer | 6 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Dabigatran: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Warfarin: Without Active Cancer | 3 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to PAC: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Edoxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Edoxaban: Without Active Cancer | 2 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to PAC: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Apixaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Apixaban: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Rivaroxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to PAC: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Edoxaban: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Rivaroxaban: Without Active Cancer | 2 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Warfarin: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Edoxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Warfarin: Without Active Cancer | 4 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Apixaban: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Warfarin: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Warfarin: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Dabigatran: Without Active Cancer | 2 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Apixaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to PAC: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Dabigatran: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Rivaroxaban: Without Active Cancer | 6 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Rivaroxaban: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to PAC: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Warfarin: Without Active Cancer | 28 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Apixaban: Without Active Cancer | 13 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Dabigatran: Without Active Cancer | 4 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Edoxaban: Without Active Cancer | 20 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Warfarin: With Active Cancer | 2 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to PAC: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Apixaban: With Active Cancer | 2 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Dabigatran: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Edoxaban: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to PAC: Without Active Cancer | 10 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Dabigatran: Without Active Cancer | 4 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Dabigatran: With Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to NOAC: With Active Cancer | 7 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to NOAC: Without Active Cancer | 29 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Warfarin: With Active Cancer | 1 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Apixaban: Without Active Cancer | 5 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Edoxaban: With Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Rivaroxaban: Without Active Cancer | 16 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Edoxaban: Without Active Cancer | 5 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Apixaban: With Active Cancer | 1 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Rivaroxaban: With Active Cancer | 6 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change | Switched to Warfarin: Without Active Cancer | 10 Participants |
Primary
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding
Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event major bleeding are reported.
Time frame: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)
Population: All eligible participants. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed: participants evaluable for this outcome measure with switch event. Number Analyzed (n): participants evaluable for specified rows. n =0 as switch in the same treatment arm not feasible.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Dabigatran: Without Active Cancer | 3 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Apixaban: Without Active Cancer | 2 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Edoxaban: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Dabigatran: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Apixaban: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to PAC: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to NOAC: Without Active Cancer | 17 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to NOAC: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to PAC: Without Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Rivaroxaban: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Rivaroxaban: Without Active Cancer | 12 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Edoxaban: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Warfarin: Without Active Cancer | 5 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to PAC: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Warfarin: With Active Cancer | 1 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to PAC: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Dabigatran: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Warfarin: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Rivaroxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to PAC: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Rivaroxaban: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Dabigatran: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Warfarin: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to PAC: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Edoxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Edoxaban: Without Active Cancer | 3 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to PAC: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Apixaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Apixaban: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Rivaroxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to PAC: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Edoxaban: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Rivaroxaban: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Warfarin: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Edoxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Warfarin: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Apixaban: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Warfarin: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Warfarin: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Dabigatran: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Apixaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to PAC: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Dabigatran: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Rivaroxaban: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Rivaroxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to PAC: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Warfarin: Without Active Cancer | 4 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Apixaban: Without Active Cancer | 9 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Dabigatran: Without Active Cancer | 2 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Edoxaban: Without Active Cancer | 3 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Warfarin: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to PAC: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Apixaban: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Dabigatran: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Edoxaban: With Active Cancer | 2 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to PAC: Without Active Cancer | 1 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Dabigatran: Without Active Cancer | 1 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Dabigatran: With Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to NOAC: With Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to NOAC: Without Active Cancer | 11 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Warfarin: With Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Apixaban: Without Active Cancer | 1 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Edoxaban: With Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Rivaroxaban: Without Active Cancer | 7 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Edoxaban: Without Active Cancer | 2 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Apixaban: With Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Rivaroxaban: With Active Cancer | 0 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding | Switched to Warfarin: Without Active Cancer | 5 Participants |
Primary
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery
Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event major surgery are reported.
Time frame: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)
Population: All eligible participants. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed: participants evaluable for this outcome measure with switch event. Number Analyzed (n): participants evaluable for specified rows. n =0 as switch in the same treatment arm not feasible.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Dabigatran: Without Active Cancer | 4 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Apixaban: Without Active Cancer | 1 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Edoxaban: With Active Cancer | 1 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Dabigatran: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Apixaban: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to PAC: With Active Cancer | 1 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to NOAC: Without Active Cancer | 26 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to NOAC: With Active Cancer | 3 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to PAC: Without Active Cancer | 3 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Rivaroxaban: With Active Cancer | 2 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Rivaroxaban: Without Active Cancer | 18 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Edoxaban: Without Active Cancer | 3 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Warfarin: Without Active Cancer | 13 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to PAC: Without Active Cancer | 6 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Warfarin: With Active Cancer | 2 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to PAC: With Active Cancer | 3 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Dabigatran: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Warfarin: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Rivaroxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to PAC: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Rivaroxaban: Without Active Cancer | 2 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Dabigatran: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Warfarin: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to PAC: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Edoxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Edoxaban: Without Active Cancer | 4 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to PAC: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Apixaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Apixaban: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Rivaroxaban: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to PAC: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Edoxaban: Without Active Cancer | 2 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Rivaroxaban: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Warfarin: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Edoxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Warfarin: Without Active Cancer | 2 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Apixaban: Without Active Cancer | 2 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Warfarin: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Warfarin: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Dabigatran: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Apixaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to PAC: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Dabigatran: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Rivaroxaban: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Rivaroxaban: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to PAC: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Warfarin: Without Active Cancer | 10 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Apixaban: Without Active Cancer | 11 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Dabigatran: Without Active Cancer | 5 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Edoxaban: Without Active Cancer | 8 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Warfarin: With Active Cancer | 2 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to PAC: With Active Cancer | 2 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Apixaban: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Dabigatran: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Edoxaban: With Active Cancer | 3 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to PAC: Without Active Cancer | 5 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Dabigatran: Without Active Cancer | 5 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Dabigatran: With Active Cancer | 5 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to NOAC: With Active Cancer | 18 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to NOAC: Without Active Cancer | 65 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Warfarin: With Active Cancer | 2 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Apixaban: Without Active Cancer | 11 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Edoxaban: With Active Cancer | 2 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Rivaroxaban: Without Active Cancer | 36 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Edoxaban: Without Active Cancer | 10 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Apixaban: With Active Cancer | 2 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Rivaroxaban: With Active Cancer | 9 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery | Switched to Warfarin: Without Active Cancer | 14 Participants |
Primary
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism
Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event thromboembolism are reported.
Time frame: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)
Population: All eligible participants. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed: participants evaluable for this outcome measure with switch event. Number Analyzed (n): participants evaluable for specified rows. n =0 as switch in the same treatment arm not feasible.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Apixaban: Without Active Cancer | 8 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Edoxaban: Without Active Cancer | 7 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Dabigatran: Without Active Cancer | 9 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Dabigatran: With Active Cancer | 3 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Rivaroxaban: With Active Cancer | 8 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Apixaban: With Active Cancer | 1 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Edoxaban: With Active Cancer | 0 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to PAC: With Active Cancer | 7 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to NOAC: With Active Cancer | 12 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to NOAC: Without Active Cancer | 108 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to PAC: Without Active Cancer | 5 Participants |
| Warfarin-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Rivaroxaban: Without Active Cancer | 85 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Warfarin: Without Active Cancer | 59 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to PAC: Without Active Cancer | 15 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to PAC: With Active Cancer | 9 Participants |
| NOAC-Based Therapy | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Warfarin: With Active Cancer | 9 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to PAC: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Dabigatran: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Dabigatran: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Warfarin: Without Active Cancer | 6 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Warfarin: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Rivaroxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Edoxaban: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Rivaroxaban: Without Active Cancer | 14 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to PAC: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Edoxaban: Without Active Cancer | 9 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Apixaban: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Edoxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Rivaroxaban: With Active Cancer | 3 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Warfarin: Without Active Cancer | 3 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to PAC: Without Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Edoxaban: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Rivaroxaban: Without Active Cancer | 6 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Warfarin: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to PAC: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Apixaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Dabigatran: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Dabigatran: Without Active Cancer | 3 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Warfarin: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Apixaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Warfarin: Without Active Cancer | 2 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Apixaban: Without Active Cancer | 4 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Rivaroxaban: With Active Cancer | 0 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Rivaroxaban: Without Active Cancer | 9 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to PAC: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to PAC: Without Active Cancer | 1 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Apixaban: Without Active Cancer | 30 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Edoxaban: Without Active Cancer | 25 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to PAC: Without Active Cancer | 13 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Edoxaban: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Warfarin: With Active Cancer | 8 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Warfarin: Without Active Cancer | 48 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to PAC: With Active Cancer | 8 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Dabigatran: With Active Cancer | 1 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Apixaban: With Active Cancer | 4 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Dabigatran: Without Active Cancer | 15 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to NOAC: Without Active Cancer | 51 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Rivaroxaban: Without Active Cancer | 36 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Edoxaban: Without Active Cancer | 6 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Edoxaban: With Active Cancer | 1 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Apixaban: With Active Cancer | 1 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Dabigatran: With Active Cancer | 1 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Dabigatran: Without Active Cancer | 3 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Warfarin: Without Active Cancer | 12 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to NOAC: With Active Cancer | 8 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Apixaban: Without Active Cancer | 6 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Warfarin: With Active Cancer | 4 Participants |
| PAC Only | Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism | Switched to Rivaroxaban: With Active Cancer | 5 Participants |
Primary
Number of Participants With Interruption in Index Anticoagulant Treatment
Treatment interruption was defined as when a participant had a gap with no new treatment within 30 days of the estimated end of supply of index treatment, but subsequently restarted the index treatment after this period of 30 days. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event.
Time frame: From index date up to treatment interruption, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)
Population: Analysis population included all eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as one entity, while individual NOAC results discriminated between each NOAC, therefore total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Here, Number Analyzed signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Warfarin-Based Therapy | Number of Participants With Interruption in Index Anticoagulant Treatment | Without Active Cancer | 3429 Participants |
| Warfarin-Based Therapy | Number of Participants With Interruption in Index Anticoagulant Treatment | With Active Cancer | 172 Participants |
| NOAC-Based Therapy | Number of Participants With Interruption in Index Anticoagulant Treatment | Without Active Cancer | 8169 Participants |
| NOAC-Based Therapy | Number of Participants With Interruption in Index Anticoagulant Treatment | With Active Cancer | 961 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Interruption in Index Anticoagulant Treatment | Without Active Cancer | 965 Participants |
| NOAC-Based Therapy: Apixaban | Number of Participants With Interruption in Index Anticoagulant Treatment | With Active Cancer | 115 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Interruption in Index Anticoagulant Treatment | Without Active Cancer | 492 Participants |
| NOAC-Based Therapy: Dabigatran | Number of Participants With Interruption in Index Anticoagulant Treatment | With Active Cancer | 51 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Interruption in Index Anticoagulant Treatment | Without Active Cancer | 439 Participants |
| NOAC-Based Therapy: Edoxaban | Number of Participants With Interruption in Index Anticoagulant Treatment | With Active Cancer | 38 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Interruption in Index Anticoagulant Treatment | Without Active Cancer | 5973 Participants |
| NOAC-Based Therapy: Rivaroxaban | Number of Participants With Interruption in Index Anticoagulant Treatment | With Active Cancer | 728 Participants |
| PAC Only | Number of Participants With Interruption in Index Anticoagulant Treatment | Without Active Cancer | 1226 Participants |
| PAC Only | Number of Participants With Interruption in Index Anticoagulant Treatment | With Active Cancer | 401 Participants |
Primary
Overall Index Anticoagulant Treatment Duration
Overall anticoagulant treatment duration was defined as the time period from the index date to the earliest of treatment interruption, switch, or discontinuation. Treatment interruption: when a participant had a gap with no new treatment within 30 days of estimated end of supply of index treatment, but subsequently restarted index treatment after this period of 30 days. Treatment switching: a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Treatment discontinuation: when a participant who ended their first continuous treatment episode with index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event.
Time frame: From index date up to the earliest of treatment interruption, switch, or discontinuation; during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)
Population: Analysis population included all eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as one entity, while individual NOAC results discriminated between each NOAC, therefore total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Here, Number Analyzed signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Warfarin-Based Therapy | Overall Index Anticoagulant Treatment Duration | Without Active Cancer | 139 Days |
| Warfarin-Based Therapy | Overall Index Anticoagulant Treatment Duration | With Active Cancer | 80 Days |
| NOAC-Based Therapy | Overall Index Anticoagulant Treatment Duration | Without Active Cancer | 140 Days |
| NOAC-Based Therapy | Overall Index Anticoagulant Treatment Duration | With Active Cancer | 111 Days |
| NOAC-Based Therapy: Apixaban | Overall Index Anticoagulant Treatment Duration | Without Active Cancer | 96 Days |
| NOAC-Based Therapy: Apixaban | Overall Index Anticoagulant Treatment Duration | With Active Cancer | 104 Days |
| NOAC-Based Therapy: Dabigatran | Overall Index Anticoagulant Treatment Duration | Without Active Cancer | 137 Days |
| NOAC-Based Therapy: Dabigatran | Overall Index Anticoagulant Treatment Duration | With Active Cancer | 105 Days |
| NOAC-Based Therapy: Edoxaban | Overall Index Anticoagulant Treatment Duration | Without Active Cancer | 164 Days |
| NOAC-Based Therapy: Edoxaban | Overall Index Anticoagulant Treatment Duration | With Active Cancer | 123 Days |
| NOAC-Based Therapy: Rivaroxaban | Overall Index Anticoagulant Treatment Duration | Without Active Cancer | 128 Days |
| NOAC-Based Therapy: Rivaroxaban | Overall Index Anticoagulant Treatment Duration | With Active Cancer | 102 Days |
| PAC Only | Overall Index Anticoagulant Treatment Duration | Without Active Cancer | 3 Days |
| PAC Only | Overall Index Anticoagulant Treatment Duration | With Active Cancer | 34 Days |
Primary
Time to Treatment Discontinuation
Treatment discontinuation (complete discontinuation; no reinitiation) was defined as when a participant who ended their first continuous treatment episode with the index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time. The time to treatment discontinuation was defined as the period from the index date to the date of treatment discontinuation. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event.
Time frame: From index date up to treatment discontinuation, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)
Population: All eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC,hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed:participants evaluable for this outcome measure with discontinuation event;Number Analyzed:participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Warfarin-Based Therapy | Time to Treatment Discontinuation | Without Active Cancer | 129 Days |
| Warfarin-Based Therapy | Time to Treatment Discontinuation | With Active Cancer | 75 Days |
| NOAC-Based Therapy | Time to Treatment Discontinuation | Without Active Cancer | 119 Days |
| NOAC-Based Therapy | Time to Treatment Discontinuation | With Active Cancer | 101 Days |
| NOAC-Based Therapy: Apixaban | Time to Treatment Discontinuation | Without Active Cancer | 84 Days |
| NOAC-Based Therapy: Apixaban | Time to Treatment Discontinuation | With Active Cancer | 99 Days |
| NOAC-Based Therapy: Dabigatran | Time to Treatment Discontinuation | Without Active Cancer | 134 Days |
| NOAC-Based Therapy: Dabigatran | Time to Treatment Discontinuation | With Active Cancer | 118 Days |
| NOAC-Based Therapy: Edoxaban | Time to Treatment Discontinuation | Without Active Cancer | 154 Days |
| NOAC-Based Therapy: Edoxaban | Time to Treatment Discontinuation | With Active Cancer | 112 Days |
| NOAC-Based Therapy: Rivaroxaban | Time to Treatment Discontinuation | Without Active Cancer | 119 Days |
| NOAC-Based Therapy: Rivaroxaban | Time to Treatment Discontinuation | With Active Cancer | 97 Days |
| PAC Only | Time to Treatment Discontinuation | Without Active Cancer | 2 Days |
| PAC Only | Time to Treatment Discontinuation | With Active Cancer | 25 Days |
Primary
Time to Treatment Interruption
Treatment interruption was defined as when a participant had a gap with no new treatment within 30 days of the estimated end of supply of index treatment, but subsequently restarted the index treatment after this period of 30 days. The time to treatment interruption was defined as the period from the index date to the date of treatment interruption. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event.
Time frame: From index date up to treatment interruption, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)
Population: All eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed: participants evaluable for this outcome measure with interruption event;Number Analyzed: participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Warfarin-Based Therapy | Time to Treatment Interruption | Without Active Cancer | 163 Days |
| Warfarin-Based Therapy | Time to Treatment Interruption | With Active Cancer | 129 Days |
| NOAC-Based Therapy | Time to Treatment Interruption | With Active Cancer | 137 Days |
| NOAC-Based Therapy | Time to Treatment Interruption | Without Active Cancer | 129 Days |
| NOAC-Based Therapy: Apixaban | Time to Treatment Interruption | Without Active Cancer | 86 Days |
| NOAC-Based Therapy: Apixaban | Time to Treatment Interruption | With Active Cancer | 123 Days |
| NOAC-Based Therapy: Dabigatran | Time to Treatment Interruption | Without Active Cancer | 137 Days |
| NOAC-Based Therapy: Dabigatran | Time to Treatment Interruption | With Active Cancer | 119 Days |
| NOAC-Based Therapy: Edoxaban | Time to Treatment Interruption | Without Active Cancer | 130 Days |
| NOAC-Based Therapy: Edoxaban | Time to Treatment Interruption | With Active Cancer | 159 Days |
| NOAC-Based Therapy: Rivaroxaban | Time to Treatment Interruption | Without Active Cancer | 128 Days |
| NOAC-Based Therapy: Rivaroxaban | Time to Treatment Interruption | With Active Cancer | 134 Days |
| PAC Only | Time to Treatment Interruption | With Active Cancer | 61 Days |
| PAC Only | Time to Treatment Interruption | Without Active Cancer | 3 Days |
Primary
Time to Treatment Switch
Treatment switching was defined as a prescription of another anticoagulant therapy that was started after the treatment initiation of the index anticoagulant treatment and within 30 days after the estimated end of supply of the index anticoagulant drug (exposure to the new anticoagulant treatment must last for at least 30 days to be considered as a treatment switch). The time to treatment switch was defined as the period from the index date to the date of treatment switch. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event.
Time frame: From index date up to treatment switch, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)
Population: All eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Overall Number of Participants Analyzed: participants evaluable for this outcome measure with switch event; Number Analyzed: participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Warfarin-Based Therapy | Time to Treatment Switch | Without Active Cancer | 57 Days |
| Warfarin-Based Therapy | Time to Treatment Switch | With Active Cancer | 36 Days |
| NOAC-Based Therapy | Time to Treatment Switch | Without Active Cancer | 179 Days |
| NOAC-Based Therapy | Time to Treatment Switch | With Active Cancer | 76 Days |
| NOAC-Based Therapy: Apixaban | Time to Treatment Switch | Without Active Cancer | 66 Days |
| NOAC-Based Therapy: Apixaban | Time to Treatment Switch | With Active Cancer | 44 Days |
| NOAC-Based Therapy: Dabigatran | Time to Treatment Switch | Without Active Cancer | 105 Days |
| NOAC-Based Therapy: Dabigatran | Time to Treatment Switch | With Active Cancer | 60 Days |
| NOAC-Based Therapy: Edoxaban | Time to Treatment Switch | Without Active Cancer | 87 Days |
| NOAC-Based Therapy: Edoxaban | Time to Treatment Switch | With Active Cancer | 98 Days |
| NOAC-Based Therapy: Rivaroxaban | Time to Treatment Switch | Without Active Cancer | 99 Days |
| NOAC-Based Therapy: Rivaroxaban | Time to Treatment Switch | With Active Cancer | 53 Days |
| PAC Only | Time to Treatment Switch | Without Active Cancer | 27 Days |
| PAC Only | Time to Treatment Switch | With Active Cancer | 49 Days |